# Agilent Technologies Moat

Status: published. Policy: company-analysis-1.

Agilent has a qualified narrow moat from integrated laboratory workflows and diagnostics equipment relationships linked to ongoing reagent purchases. Contractual disclosures support switching friction and repeat demand, although their magnitude and companywide reach are unquantified. Targeted price increases benefited results in 2024–2026, demonstrating some pricing power. Mixed margin outcomes, intense competition and continuing innovation requirements limit confidence in broader or exceptional durability.

## switching_costs

Existing diagnostics equipment leases link equipment economics to reagent shipments over the lease life, supporting repeat customer relationships and an inference of switching friction. Integrated instruments, consumables and software reinforce this advantage in some workflows; exclusivity and replacement costs are not disclosed.

Durability: The equipment-and-reagent arrangement is disclosed in both 2023 and 2025, establishing an enduring business practice rather than a proposed opportunity. Protection plausibly persists during equipment use and contractual relationships, but lease lengths, renewal outcomes and long-term customer retention are unavailable.

Risks: Intense competition and evolving standards can weaken workflow attachment. Customer funding constraints can reduce purchases even when equipment remains installed. Realized 2025 margin compression shows that targeted pricing did not fully offset cost and mix pressures; 2026 improvement also benefited from tariff refunds and other factors.

Invalidation: The thesis would weaken materially if installed customers routinely replaced Agilent workflows without meaningful disruption, used competing reagents interchangeably, or showed sustained deterioration in reagent purchases and lease renewals. Persistent price concessions accompanied by lost installed-base business would further invalidate the claimed protection.

Competitors: AB Sciex., Avecia, Bruker, Inc., Leica Biosystems, Inc., Roche Ventana Medical Systems, Inc., Shimadzu Corporation, Thermo Fisher Scientific Inc., Twist Bioscience Corporation, Waters Corporation
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087225000087/a-20251031.htm) · 2025-12-22
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087226000064/a-20260731.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087226000064/a-20260731.htm) · 2026-09-01
- [https://www.sec.gov/Archives/edgar/data/1090872/000119312526040286/a-20260203.htm](https://www.sec.gov/Archives/edgar/data/1090872/000119312526040286/a-20260203.htm) · 2026-02-06
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087224000049/a-20241031.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087224000049/a-20241031.htm) · 2024-12-20
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087223000020/a-20231031.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087223000020/a-20231031.htm) · 2023-12-20
- [https://www.sec.gov/Archives/edgar/data/1090872/000109087226000055/a-20260430.htm](https://www.sec.gov/Archives/edgar/data/1090872/000109087226000055/a-20260430.htm) · 2026-06-01

[JSON](https://beanvest.com/stock/a/moat.json)